<p>随着亚洲市场在复杂的环境中应对混合的经济指标和不断变化的投资者情绪，该地区的科技行业凭借其高增长潜力继续吸引关注。在这种环境下，识别有前景的科技股票需要寻找那些在全球趋势变化和地方挑战中展现出韧性和创新的公司。</p>
<h3>亚洲十大高增长科技公司</h3>
<table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>盛宜科技有限公司</td>
<td>21.50%</td>
<td>32.87%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>巨人网络集团</td>
<td>34.73%</td>
<td>40.54%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>福斯特科技</td>
<td>37.83%</td>
<td>51.54%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>苏州 TFC 光通信</td>
<td>35.80%</td>
<td>36.87%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>金电路电子</td>
<td>29.41%</td>
<td>37.22%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>中基光电</td>
<td>34.82%</td>
<td>35.50%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>盛宜电子</td>
<td>24.67%</td>
<td>33.32%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>eWeLL 有限公司</td>
<td>21.55%</td>
<td>22.80%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>科技发展</td>
<td>35.68%</td>
<td>75.80%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen 治疗控股</td>
<td>100.40%</td>
<td>118.16%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们亚洲高增长科技和人工智能股票筛选器的完整 187 只股票列表。</p>
<p>我们将从筛选结果中选取一些进行分析。</p>
<h2>上海 OPM 生物科学（SHSE:688293）</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 上海 OPM 生物科学有限公司专注于提供细胞培养基和 CDMO 服务，业务覆盖中国及国际市场，市值为 59 亿人民币。</p>
<p><strong>运营：</strong> OPM 生物科学主要通过其细胞培养基和 CDMO 服务产生收入。该公司在中国和国际市场均有运营，市值为 59 亿人民币。</p>
<p>上海 OPM 生物科学在竞争激烈的生物科技行业中展现出强劲的增长，2025 年前九个月收入显著增长 25.8%，达到 2.7153 亿人民币，净收入激增 81.4%，达到 4943 万人民币。这些财务收益反映出公司对研发的战略重视，这对维持技术领导地位和在亚洲高增长市场中的创新至关重要。尽管面临股价高度波动和预测的股本回报率仅为 7% 的挑战，但公司年均 46.46% 的盈利增长显著超过了中国市场的整体扩张率，展示了其在激烈行业竞争和不断变化的市场需求中的潜力。</p>
<ul>
<li>通过阅读我们的健康报告，深入了解上海 OPM 生物科学的表现。</li>
<li>通过我们的详细历史表现报告评估上海 OPM 生物科学的过去表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/24434bea-be79-43c0-b930-0c8e231fafe2/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="1048" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/24434bea-be79-43c0-b930-0c8e231fafe2/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:688293 截至 2025 年 12 月的盈利和收入增长</p>
<h2>Kakaku.com（TSE:2371）</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Kakaku.com, Inc.及其子公司在日本提供购买支持和餐厅评价服务，市值为 4543.3 亿日元。</p>
<p><strong>运营：</strong> 该公司主要通过其 Kakaku.Com 部门产生收入，贡献 240.4 亿日元，以及 Tabelog 部门的 367.5 亿日元，专注于日本的购买支持和餐厅评价。Kyujin Box 和孵化部门分别增加了 173.1 亿日元和 89.1 亿日元的额外收入，突显了其在数字服务领域的多元化商业模式。</p>
<p>Kakaku.com 以其强大的价格比较和消费者服务平台而闻名，正在不断变化的市场环境中保持着对创新的坚定承诺。公司年均 11.7% 的收入增长和 12.5% 的盈利增长超越了日本市场平均 4.6% 的扩张率。尽管在高增长领域并不处于领先地位，但 Kakaku.com 通过战略性研发投资和高质量的盈利巩固了其市场地位。近期持续分红的确认彰显了财务稳定性，吸引了寻求可靠回报的利益相关者。</p>
<ul>
<li>通过我们的综合健康报告深入了解 Kakaku.com 的复杂性。</li>
<li>通过访问我们的历史表现报告评估 Kakaku.com 的过去表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/5166ea84-bac7-4a4d-a803-a6652f4f9e2d/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="1048" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/5166ea84-bac7-4a4d-a803-a6652f4f9e2d/chart/earnings-and-revenue-growth"/></p>
<p>TSE:2371 截至 2025 年 12 月的盈利和收入增长</p>
<h2>CELSYS（TSE:3663）</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> CELSYS, Inc.在日本的内容创作解决方案领域运营，市值为 496.1 亿日元。</p>
<p><strong>运营：</strong> CELSYS, Inc.专注于在日本提供内容创作解决方案。该公司主要通过软件销售和相关服务产生收入，专注于数字插图、漫画和动画工具。</p>
<p>CELSYS 凭借其战略性的股票回购计划吸引了关注，表明其对财务健康的信心和对股东价值的承诺。这一举措与公司强劲的表现相辅相成，修订后的盈利预测超出之前预期，得益于其旗舰软件 CLIP STUDIO PAINT 的一次性购买和订阅模式的强劲销售。预计年均 27.2% 的盈利增长和每年 9% 的收入增长——均超过日本市场平均水平——使 CELSYS 在竞争激烈的科技领域中具备持续成功的潜力。</p>
<ul>
<li>点击这里访问我们的完整健康分析报告，以了解 CELSYS 的动态。</li>
<li>通过我们的过去报告获取 CELSYS 的趋势和表现的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/850a7a11-e4be-477b-8270-7d157f2aada2/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="1048" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/850a7a11-e4be-477b-8270-7d157f2aada2/chart/earnings-and-revenue-growth"/></p>
<p>TSE:3663 截至 2025 年 12 月的收益和收入增长</p>
<h2>利用优势</h2>
<ul>
<li>在这里发现 187 只亚洲高增长科技和人工智能股票的完整阵容。</li>
<li>这些股票中有哪一些是你资产组合的一部分吗？利用 Simply Wall St 的投资组合分析能力，全面了解它们的发展情况。</li>
<li>Simply Wall St 是一款为长期股票投资者设计的革命性应用，免费且覆盖全球所有市场。</li>
</ul>
<h2>对其他选项感兴趣？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司来充实你的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
<p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑你的目标或财务状况。我们的目标是为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>

巨人网络

科济药业-B

<p>亚洲科技股因其高增长潜力而备受关注，尽管经济指标参差不齐。主要公司包括盛宜科技、巨人网络集团和科济药业-B，均显示出强劲的收入和盈利增长。上海 OPM 生物科学和 Kakaku.com 因其稳健的表现和战略性研发投资而受到关注。CELSYS 因其股票回购计划和强劲的销售业绩而受到认可。Simply Wall St 提供了对 187 只高增长科技股的全面分析</p>

<p>As Asian markets navigate a complex landscape marked by mixed economic indicators and evolving investor sentiment, the region's technology sector continues to capture attention with its potential for high growth. In this environment, identifying promising tech stocks involves looking for companies that demonstrate resilience and innovation amidst shifting global trends and local challenges.</p>
<div class="lb-trans"><p>随着亚洲市场在复杂的环境中应对混合的经济指标和不断变化的投资者情绪，该地区的科技行业凭借其高增长潜力继续吸引关注。在这种环境下，识别有前景的科技股票需要寻找那些在全球趋势变化和地方挑战中展现出韧性和创新的公司。</p>
</div><h3>Top 10 High Growth Tech Companies In Asia</h3>
<div class="lb-trans"><h3>亚洲十大高增长科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shengyi TechnologyLtd</td>
<td>21.50%</td>
<td>32.87%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Giant Network Group</td>
<td>34.73%</td>
<td>40.54%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fositek</td>
<td>37.83%</td>
<td>51.54%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Suzhou TFC Optical Communication</td>
<td>35.80%</td>
<td>36.87%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Gold Circuit Electronics</td>
<td>29.41%</td>
<td>37.22%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Zhongji Innolight</td>
<td>34.82%</td>
<td>35.50%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi Electronics</td>
<td>24.67%</td>
<td>33.32%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>eWeLLLtd</td>
<td>21.55%</td>
<td>22.80%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Co-Tech Development</td>
<td>35.68%</td>
<td>75.80%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>100.40%</td>
<td>118.16%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>盛宜科技有限公司</td>
<td>21.50%</td>
<td>32.87%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>巨人网络集团</td>
<td>34.73%</td>
<td>40.54%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>福斯特科技</td>
<td>37.83%</td>
<td>51.54%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>苏州 TFC 光通信</td>
<td>35.80%</td>
<td>36.87%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>金电路电子</td>
<td>29.41%</td>
<td>37.22%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>中基光电</td>
<td>34.82%</td>
<td>35.50%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>盛宜电子</td>
<td>24.67%</td>
<td>33.32%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>eWeLL 有限公司</td>
<td>21.55%</td>
<td>22.80%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>科技发展</td>
<td>35.68%</td>
<td>75.80%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen 治疗控股</td>
<td>100.40%</td>
<td>118.16%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 187 stocks from our Asian High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们亚洲高增长科技和人工智能股票筛选器的完整 187 只股票列表。</p>
</div><p>We'll examine a selection from our screener results.</p>
<div class="lb-trans"><p>我们将从筛选结果中选取一些进行分析。</p>
</div><h2>Shanghai OPM Biosciences (SHSE:688293)</h2>
<div class="lb-trans"><h2>上海 OPM 生物科学（SHSE:688293）</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Shanghai OPM Biosciences Co., Ltd. is engaged in providing cell culture media and CDMO services both in China and internationally, with a market cap of CN¥5.90 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 上海 OPM 生物科学有限公司专注于提供细胞培养基和 CDMO 服务，业务覆盖中国及国际市场，市值为 59 亿人民币。</p>
</div><p><strong>Operations:</strong> OPM Biosciences generates revenue primarily through its cell culture media and CDMO services. The company operates both domestically in China and internationally, with a market cap of CN¥5.90 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> OPM 生物科学主要通过其细胞培养基和 CDMO 服务产生收入。该公司在中国和国际市场均有运营，市值为 59 亿人民币。</p>
</div><p>Shanghai OPM Biosciences has demonstrated robust growth in the competitive biotech sector, with a notable 25.8% increase in revenue to CNY 271.53 million and a surge in net income by 81.4% to CNY 49.43 million for the first nine months of 2025. These financial gains reflect a strategic emphasis on R&amp;D, crucial for maintaining technological leadership and innovation within Asia's high-growth markets. Despite facing challenges like a highly volatile share price and low forecasted Return on Equity at just 7%, the company's earnings growth of 46.46% annually outpaces the broader Chinese market's expansion rate significantly, showcasing its potential amidst fierce industry competition and evolving market demands.</p>
<div class="lb-trans"><p>上海 OPM 生物科学在竞争激烈的生物科技行业中展现出强劲的增长，2025 年前九个月收入显著增长 25.8%，达到 2.7153 亿人民币，净收入激增 81.4%，达到 4943 万人民币。这些财务收益反映出公司对研发的战略重视，这对维持技术领导地位和在亚洲高增长市场中的创新至关重要。尽管面临股价高度波动和预测的股本回报率仅为 7% 的挑战，但公司年均 46.46% 的盈利增长显著超过了中国市场的整体扩张率，展示了其在激烈行业竞争和不断变化的市场需求中的潜力。</p>
</div><ul>
<li>Get an in-depth perspective on Shanghai OPM Biosciences' performance by reading our health report here.</li>
<li>Assess Shanghai OPM Biosciences' past performance with our detailed historical performance reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过阅读我们的健康报告，深入了解上海 OPM 生物科学的表现。</li>
<li>通过我们的详细历史表现报告评估上海 OPM 生物科学的过去表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/24434bea-be79-43c0-b930-0c8e231fafe2/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/24434bea-be79-43c0-b930-0c8e231fafe2/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:688293 Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>SHSE:688293 截至 2025 年 12 月的盈利和收入增长</p>
</div><h2>Kakaku.com (TSE:2371)</h2>
<div class="lb-trans"><h2>Kakaku.com（TSE:2371）</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Kakaku.com, Inc., along with its subsidiaries, offers purchase support and restaurant review services in Japan and has a market capitalization of ¥454.33 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Kakaku.com, Inc.及其子公司在日本提供购买支持和餐厅评价服务，市值为 4543.3 亿日元。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily through its Kakaku.Com segment, contributing ¥24.04 billion, and Tabelog segment with ¥36.75 billion, focusing on purchase support and restaurant reviews in Japan. The Kyujin Box and Incubation segments add additional income streams of ¥17.31 billion and ¥8.91 billion respectively, highlighting a diversified business model within the digital services sector.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司主要通过其 Kakaku.Com 部门产生收入，贡献 240.4 亿日元，以及 Tabelog 部门的 367.5 亿日元，专注于日本的购买支持和餐厅评价。Kyujin Box 和孵化部门分别增加了 173.1 亿日元和 89.1 亿日元的额外收入，突显了其在数字服务领域的多元化商业模式。</p>
</div><p>Kakaku.com, renowned for its robust platform in price comparison and consumer services, is navigating through an evolving market landscape with a steady commitment to innovation. With an 11.7% annual revenue growth and a 12.5% increase in earnings per year, the company outstrips Japan's average market expansion of 4.6%. Despite not leading the pack in high-growth sectors, Kakaku.com maintains a competitive edge through strategic R&amp;D investments and high-quality earnings that solidify its market position. Recent affirmations of consistent dividends underscore financial stability, appealing to stakeholders looking for reliable returns amidst dynamic market conditions.</p>
<div class="lb-trans"><p>Kakaku.com 以其强大的价格比较和消费者服务平台而闻名，正在不断变化的市场环境中保持着对创新的坚定承诺。公司年均 11.7% 的收入增长和 12.5% 的盈利增长超越了日本市场平均 4.6% 的扩张率。尽管在高增长领域并不处于领先地位，但 Kakaku.com 通过战略性研发投资和高质量的盈利巩固了其市场地位。近期持续分红的确认彰显了财务稳定性，吸引了寻求可靠回报的利益相关者。</p>
</div><ul>
<li>Navigate through the intricacies of Kakaku.com with our comprehensive health report here.</li>
<li>Evaluate Kakaku.com's historical performance by accessing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过我们的综合健康报告深入了解 Kakaku.com 的复杂性。</li>
<li>通过访问我们的历史表现报告评估 Kakaku.com 的过去表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/5166ea84-bac7-4a4d-a803-a6652f4f9e2d/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/5166ea84-bac7-4a4d-a803-a6652f4f9e2d/chart/earnings-and-revenue-growth"/></p>
<p>TSE:2371 Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>TSE:2371 截至 2025 年 12 月的盈利和收入增长</p>
</div><h2>CELSYS (TSE:3663)</h2>
<div class="lb-trans"><h2>CELSYS（TSE:3663）</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> CELSYS, Inc. operates in the content creation solutions sector in Japan and has a market capitalization of ¥49.61 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> CELSYS, Inc.在日本的内容创作解决方案领域运营，市值为 496.1 亿日元。</p>
</div><p><strong>Operations:</strong> CELSYS, Inc. specializes in providing content creation solutions within Japan. The company generates revenue primarily through software sales and related services, focusing on digital illustration, manga, and animation tools.</p>
<div class="lb-trans"><p><strong>运营：</strong> CELSYS, Inc.专注于在日本提供内容创作解决方案。该公司主要通过软件销售和相关服务产生收入，专注于数字插图、漫画和动画工具。</p>
</div><p>CELSYS is capturing attention with its strategic share repurchase program, signaling confidence in its financial health and commitment to shareholder value. This initiative complements the company's robust performance, highlighted by a revised earnings forecast that surpasses previous expectations due to strong sales from both one-time purchases and subscription models of its flagship software, CLIP STUDIO PAINT. With an impressive 27.2% expected annual earnings growth and a revenue increase of 9% per year—outpacing the Japanese market average—CELSYS is poised for continued success in the competitive tech landscape.</p>
<div class="lb-trans"><p>CELSYS 凭借其战略性的股票回购计划吸引了关注，表明其对财务健康的信心和对股东价值的承诺。这一举措与公司强劲的表现相辅相成，修订后的盈利预测超出之前预期，得益于其旗舰软件 CLIP STUDIO PAINT 的一次性购买和订阅模式的强劲销售。预计年均 27.2% 的盈利增长和每年 9% 的收入增长——均超过日本市场平均水平——使 CELSYS 在竞争激烈的科技领域中具备持续成功的潜力。</p>
</div><ul>
<li>Click here and access our complete health analysis report to understand the dynamics of CELSYS.</li>
<li>Gain insights into CELSYS' past trends and performance with our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里访问我们的完整健康分析报告，以了解 CELSYS 的动态。</li>
<li>通过我们的过去报告获取 CELSYS 的趋势和表现的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/850a7a11-e4be-477b-8270-7d157f2aada2/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/850a7a11-e4be-477b-8270-7d157f2aada2/chart/earnings-and-revenue-growth"/></p>
<p>TSE:3663 Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>TSE:3663 截至 2025 年 12 月的收益和收入增长</p>
</div><h2>Taking Advantage</h2>
<div class="lb-trans"><h2>利用优势</h2>
</div><ul>
<li>Discover the full array of 187 Asian High Growth Tech and AI Stocks right here.</li>
<li>Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.</li>
<li>Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里发现 187 只亚洲高增长科技和人工智能股票的完整阵容。</li>
<li>这些股票中有哪一些是你资产组合的一部分吗？利用 Simply Wall St 的投资组合分析能力，全面了解它们的发展情况。</li>
<li>Simply Wall St 是一款为长期股票投资者设计的革命性应用，免费且覆盖全球所有市场。</li>
</ul>
</div><h2>Curious About Other Options?</h2>
<div class="lb-trans"><h2>对其他选项感兴趣？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司来充实你的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑你的目标或财务状况。我们的目标是为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div>

2025 年 12 月亚洲高增长科技股值得关注